Biotech Archives - Page 92 of 795

2 minute read

Analysts Eye Summit Therapeutics’ Ivonescimab As Potential Challenger To Merck’s Keytruda in Lung Cancer Treatment

March 26, 2:36 PM

Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in 2024 and a $5 billion deal add to the optimism, signaling potential share price growth ahead.

MRK

2 minute read

Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly

By Vandana Singh

March 26, 1:48 PM

Biohaven's approach to combat obesity. Learn about their experimental drug taldefgrobep alfa (t-alpha), targeting muscle growth regulation for effective weight loss. CEO Vlad Coric discusses its potential to preserve muscle mass, boost metabolism, and induce weight loss.

BHVN

2 minute read

Fortrea Increases Patient Access Capabilities And Cold Chain Expertise With FortreaRx Expansion

By Benzinga Newsdesk

February 20, 5:25 PM

Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the opening of its expanded non-commercial specialty pharmacy, FortreaRx™, located in Lake Mary,

FTRE

2 minute read

Tharimmune’s Oral ‘Under The Cheek’ Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease

By Vandana Singh

February 20, 5:10 PM

Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential for liver-related conditions.

THAR

2 minute read

ARS Pharma Readies Data In Response To FDA’s Rejection For Its EpiPen Alternative For Severe Allergic Reactions

By Vandana Singh

February 20, 3:53 PM

NAC study results by ARS Pharma comparing neffy (epinephrine nasal spray) to intramuscular injection. Data submission is expected in Q2 2024.

SPRY

2 minute read

Teva Pharma CEO Dismisses Split Speculations Expects Significant Interest For Its API Business Divestiture: Report

By Vandana Singh

February 20, 2:24 PM

Teva Pharmaceutical Industries confirms unity and dispels split rumors. CEO Richard Francis emphasizes the synergy between generics and branded drugs.

TEVA

2 minute read

Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones

By Vandana Singh

February 20, 2:05 PM

Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth.

AXSM

1 minute read

Why Is Cancer Drug Focused Monopar Therapeutics Stock Trading Higher On Tuesday?

By Vandana Singh

February 20, 1:48 PM

Monopar Therapeutics surges 90% premarket with 3.94 million volume after HREC clearance for Phase 1 dosimetry trial (MNPR-101-Zr) in advanced cancers.

MNPR

2 minute read

What’s Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

By Vandana Singh

February 20, 1:30 PM

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

CMMB